 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...131132133134135136137138139140141...858859» |
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System (Ballroom 20D; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1755;
Avacopan users quickly tapered prednisone doses but low-to-moderate doses of prednisone were commonly used for prolonged periods. Nearly one-in-five patients experienced a flare.
- Erelzi (etanercept-szzs) / Sandoz, Enbrel (etanercept) / Pfizer, Amgen
Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections (Room 6E/6D; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1730;
The NTM device effectively infused etanercept into the peripheral lymphatics that drain to the LN. The NTM device was well accepted by all patients with an application pain rating of 3.8
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Review, Journal: Pharmacological agents for bone fracture healing: talking points from recent clinical trials. (Pubmed Central) - Sep 23, 2023
Concerning the effect of parathormone, current level I evidence is controversial, and additional studies are required. Level I, systematic review of RCTs.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Observation Of Denosumab Discontinuation Without Further Treatment in Clinical Practice. (Pubmed Central) - Sep 22, 2023
Level I, systematic review of RCTs. No abstract available
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure. (Pubmed Central) - Sep 22, 2023
No abstract available No abstract available
- | Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival. (Pubmed Central) - Sep 22, 2023
X1 or SC18 also had synergistic effects with sorafenib on promoting cell death at 0.5-2 IC for SC18 in Huh7 and SNU-449?cells. These results suggest that small molecules targeting VDAC represent a potential new class of drugs to treat liver cancer.
- | Stivarga (regorafenib) / Bayer
Journal: Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells. (Pubmed Central) - Sep 22, 2023
Furthermore, mouse xenograft models demonstrated that synergistic anti-tumor effects of combined treatment with regorafenib and oxaliplatin. This study provided solid experimental evidences for the combined treatment with regorafenib and oxaliplatin in CRC.
- | Vectibix (panitumumab) / Amgen
Trial primary completion date: Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 22, 2023
P2, N=60, Not yet recruiting, Sponsor: Andrei Iagaru
This study provided solid experimental evidences for the combined treatment with regorafenib and oxaliplatin in CRC. Trial primary completion date: Jun 2024 --> Dec 2024
- | Imdelltra (tarlatamab-dlle) / Amgen
Trial completion date: DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) - Sep 22, 2023
P1b, N=41, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: May 2025 --> Aug 2025
- | Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date: REGINA: Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (clinicaltrials.gov) - Sep 22, 2023
P2, N=60, Recruiting, Sponsor: Jules Bordet Institute
Trial completion date: May 2025 --> Aug 2025 Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2023 --> Jan 2025
- | Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Trial completion date, Mismatch repair: Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (clinicaltrials.gov) - Sep 22, 2023
P1, N=52, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2023 --> Jan 2025 Trial completion date: Jun 2024 --> Dec 2023
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 22, 2023
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2024 --> Dec 2023 Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, IO biomarker, Surgery: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 22, 2023
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026 Suspended --> Active, not recruiting
- || zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial completion, Trial completion date, Monotherapy: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2023
P1, N=11, Completed, Sponsor: Amgen
Suspended --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
- AMG 193 / Amgen
Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors (Level 2, Exhibit Hall D) - Sep 22, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_728;
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Fast Track Use of PCSK9i in Acute Coronary Syndromes in Real World Practice. Insights From the AT-TARGET-IT Registry (Zone 3, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_8178;
Early PCSK9i administration effectively reduces LDL-C in ACS patients in the real-world setting. However, concomitant LLT is needed to optimize early LDL.values.
- Repatha (evolocumab) / Amgen, Astellas
104-Week Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab in Patients With Familial Hypercholesterolemia/Hypercholesterolemia in Japan: Results of Post-Marketing Surveillance (Zone 3, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7772;
There were no trends between the lowest achieved LDL-C levels and adverse events in Japanese patients. Evolocumab was well tolerated and sustained LDL-C reduction in patients with FH and HC in a real-world clinical setting in Japan.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Hardly a Windfall: Prescribing Practices in Pediatric Heart Failure Before and After Food and Drug Administration Approval (Zone 2, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7725;
The two FDA approved medications are used in =5% of patients. While FDA approval is important, it did not substantially influence physician prescribing behavior for PHF.
- omecamtiv mecarbil (AMG 423) / Amgen, Servier
The Combined Effect of Omecamtiv Mecarbil and Low-Dose Dobutamine for Post-Arrest Myocardial Dysfunction in a Rat Model of Cardiac Arrest (Zone 2, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7449;
Both OM and LDb improved post-arrest myocardial dysfunction, cardiac mitochondrial injury, survival, neurological recovery following cardiac arrest. However, OM+LDb group did not exert synergistic effect in ameliorate post-arrest myocardial dysfunction.
- hydralazine hydrochloride / Generic mfg., isosorbide dinitrate / Generic mfg., ivabradine / Generic mfg.
Utilization of Heart Failure Therapies: Assessing Trends and Adoption of Updated Guideline Directed Medical Therapy Following the 2022 Heart Failure Guideline Release (Zone 2, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_6406;
Notably, utilization of ARNIs and SGLT2 inhibitors significantly increased. However, prescription rates for these novel therapies were below 50%, highlighting the need to expand access to a larger proportion of HFrEF patients.
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Effects of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Inflammatory and Haemostatic Parameters in Coronary Artery Disease Patients (Zone 1, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_6268;
Patients received alirocumab or evolocumab (150mg sc or 140g sc every two weeks; respectively) or placebo for 6 months. Our results show that fibrinolytic parameters and inflammatory cytokines are related to the concentration of LDL-C and not Lp(a) before and with neither of them after treatment with PCSK9i.
- | Ibrance (palbociclib) / Pfizer
Journal, IO biomarker: p21 prevents the exhaustion of CD4+ T cells within the antitumor immune response against colorectal cancer. (Pubmed Central) - Sep 21, 2023
Our data reveal the importance of p21 in controlling cell cycle and preventing exhaustion of Th1 cells. Furthermore, we unveil the therapeutic potential of CDK inhibitors such as Palbociclib to reduce T cell exhaustion for future treatment of patients with colorectal cancer.
- | Ibrance (palbociclib) / Pfizer
Journal: Palbociclib releases the latent differentiation capacity of neuroblastoma cells. (Pubmed Central) - Sep 21, 2023
Furthermore, dual treatment with retinoic acid resets the oncogenic adrenergic core regulatory circuit of neuroblastoma cells, further suppresses proliferation, and can enhance differentiation, altering gene expression in ways that significantly correlate with improved patient survival. We therefore identify palbociclib as a therapeutic approach to dramatically enhance neuroblastoma differentiation efficacy that could be used in combination with retinoic acid to improve patient outcomes.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Metastases: Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. (Pubmed Central) - Sep 21, 2023
A wide interindividual variability in therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) palbociclib, ribociclib and abemaciclib, among patients with HR+/HER2- metastatic breast cancer has been reported. Homozygous carriers of the ABCB1 T-T-T(A) haplotype tended to have a higher mean ribociclib C (934.0
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date: Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype (clinicaltrials.gov) - Sep 21, 2023
P4, N=45, Not yet recruiting, Sponsor: University of Michigan Rogel Cancer Center
Homozygous carriers of the ABCB1 T-T-T(A) haplotype tended to have a higher mean ribociclib C (934.0 Trial completion date: Aug 2026 --> Dec 2026 | Initiation date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2026 --> Dec 2026
- | Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: A Phase II Study of Neoadjuvant Sotorasib in Combination with Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS P.G12C Mutation (clinicaltrials.gov) - Sep 21, 2023
P2, N=27, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2026 --> Dec 2026 | Initiation date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2026 --> Dec 2026 Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
- || Tirazone (tirapazamine) / Teclison, SRI International
Trial completion date, Trial primary completion date, Metastases: KEYNOTE-A91: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC (clinicaltrials.gov) - Sep 21, 2023
P2, N=110, Recruiting, Sponsor: Teclison Ltd.
Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- | Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 21, 2023
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
- | Rituxan (rituximab) / Roche
Enrollment change, Trial completion date, Trial primary completion date: Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov) - Sep 21, 2023
P2, N=26, Recruiting, Sponsor: University of Wisconsin, Madison
Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025 N=46 --> 26 | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Apr 2024 --> Dec 2024
- |||| temozolomide/perillyl alcohol conjugate (NEU001) / NeOnc Technologies, NeuCen BioMed
New P1/2 trial, IO biomarker: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=134, Not yet recruiting, Sponsor: Neonc Technologies, Inc.
- ||| zamaporvint (RXC004) / Redx
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: KEYNOTE-E86: A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (clinicaltrials.gov) - Sep 21, 2023
P2, N=45, Active, not recruiting, Sponsor: Redx Pharma Plc
N=46 --> 26 | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Apr 2024 --> Dec 2024 Recruiting --> Active, not recruiting | N=80 --> 45 | Trial primary completion date: Jun 2023 --> Nov 2023
- | Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Impact of Erythropoietin on Hematological Adaptations and Physical Performance (clinicaltrials.gov) - Sep 21, 2023
P4, N=8, Completed, Sponsor: United States Army Research Institute of Environmental Medicine
Recruiting --> Active, not recruiting | N=80 --> 45 | Trial primary completion date: Jun 2023 --> Nov 2023 Recruiting --> Completed | N=24 --> 8 | Trial primary completion date: Dec 2022 --> Apr 2023
- | Parsabiv (etelcalcetide) / Amgen
Trial completion, Enrollment change: Parsabiv-MBD: The Effect of Etelcalcetide on CKD-MBD (clinicaltrials.gov) - Sep 21, 2023
P2, N=22, Completed, Sponsor: Thomas Nickolas, MD MS
Recruiting --> Completed | N=24 --> 8 | Trial primary completion date: Dec 2022 --> Apr 2023 Recruiting --> Completed | N=35 --> 22
- | Journal: Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. (Pubmed Central) - Sep 21, 2023
Many of these molecules have been shown to be effective in reducing proteinuria and stabilizing kidney function in different complement-mediated kidney diseases. Thanks to their efficacy and target specificity, these novel drugs may radically improve the outcome of complement-mediated kidney diseases, contributing to an improvement in our understanding of their underlying pathophysiology.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: Inference on tree-structured subgroups with subgroup size and subgroup effect relationship in clinical trials. (Pubmed Central) - Sep 21, 2023
Possible accommodations to post hoc identified tree-structure subgroups are also discussed in the paper. We demonstrate the merit of our proposed method by re-analyzing the panitumumab trial with the proposed method.
- | Ubrelvy (ubrogepant) / AbbVie, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: A Bibliometric and Scientific Knowledge Map Study of Migraine Treatment from 2013 to 2022. (Pubmed Central) - Sep 21, 2023
The current research mainly focuses on CGRP-related therapeutics, such as fremanezumab, erenumab and ubrogepant. Based on the analysis of bibliometric data on migraine treatment over the past decade, the trends and the knowledge graph of the country, organization, author, reference, and the keyword were identified, providing accurate and quick positioning of the critical information in the domain.
- || Strensiq (asfotase alfa) / AstraZeneca, Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review. (Pubmed Central) - Sep 21, 2023
Nine patients (32.1%) received antiresorptive medication (bisphosphonate and/or denosumab), and two patients (7.1%) received teriparatide prior to the development of AFF...Four (14.3%) and seven (25.0%) patients received asfotase alfa and teriparatide after sustaining AFF...Based on the limited evidence, AFF occurred in up to 10% of patients with HPP. Based on the 28 case reports, about two-thirds did not receive antiresorptive treatment, suggesting that the HPP itself could potentially be a risk factor for AFF.
- || Stivarga (regorafenib) / Bayer
P1 data, Journal, Combination therapy, Metastases: A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer. (Pubmed Central) - Sep 21, 2023
P1a/1b
Nofazinlimab monotherapy was well tolerated and demonstrated preliminary anti-tumor activity in multiple tumor types. Regorafenib plus nofazinlimab had a manageable safety profile but was not associated with any response in mCRC.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study. (Pubmed Central) - Sep 20, 2023
Regorafenib plus nofazinlimab had a manageable safety profile but was not associated with any response in mCRC. No abstract available
- | Stivarga (regorafenib) / Bayer
Journal: Comparative MIP sensor technique: photopolymerization or thermal polymerization for the sensitive determination (Pubmed Central) - Sep 20, 2023
Regorafenib (REG) is a diphenylurea derivative oral multikinase inhibitor. The selectivity of the sensor for REG
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab Improves Glycaemic Parameters in Postmenopausal Osteoporosis Patients with Combined Type 2 Diabetes Mellitus. (Pubmed Central) - Sep 20, 2023
Serum GLP-1 and DPP-4 levels in the I.G. did not change compared with those before treatment. In conclusion, In the clinical management of postmenopausal osteoporosis patients with combined T2DM, the choice of RANKL inhibitors as anti-osteoporosis therapy may benefit their glycaemic parameters by elevating serum active GLP-1 levels and decreasing serum DPP-4 levels.
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary Prophylaxis. (Pubmed Central) - Sep 20, 2023
Additionally, 9 patients (15%) required an additional median (IQR) of 2 (2-5) doses of filgrastim, and 9 (15%) patients were transitioned to pegfilgrastim. These results suggest that additional measures such as tracking postnadir absolute neutrophil counts should be performed to ensure patients receive an appropriate number of filgrastim doses to prevent complications associated with neutropenia/febrile neutropenia.
- | Lumakras (sotorasib) / Amgen
Journal: Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring. (Pubmed Central) - Sep 20, 2023
Subsequently, we applied the developed method to estimate sotorasib concentrations in a patient with KRAS G12C-mutated non-small cell lung cancer. We anticipate that our HPLC-UV method will be valuable for assessing the safety and efficacy of sotorasib in larger patient cohorts.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. (Pubmed Central) - Sep 19, 2023
We anticipate that our HPLC-UV method will be valuable for assessing the safety and efficacy of sotorasib in larger patient cohorts. We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal, Stroma: Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. (Pubmed Central) - Sep 19, 2023
In this narrative review, we describe the results of clinical trials that evaluated the pharmacokinetics, pharmacodynamics, efficacy and safety of tezepelumab in patients with moderate-to-severe asthma. We also introduce the ongoing clinical trials in patients with asthma as well as future trials investigating the use of tezepelumab for other indications.
- || Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Review, Journal, Metastases: KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. (Pubmed Central) - Sep 19, 2023
Where available, next-generation sequencing is recommended to facilitate simultaneous testing of potentially actionable biomarkers in a single run to conserve tissue. Results from molecular testing should inform clinical decisions in treating patients with KRAS G12C-mutated advanced NSCLC.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Journal: Protein Expression and Purification of Romiplostim and Analysis of Its Secretory Production Using an In Silico Investigated Signal Peptide in E. Coli. (Pubmed Central) - Sep 19, 2023
Despite the results of in-silico prediction, the pelB signal peptide could not transport the protein into the periplasm or extracellular environment in the experimental condition. Trying different signal peptides and more in-silico analysis might be helpful for the efficient secretion of the Romiplostim protein.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review: Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review. (Pubmed Central) - Sep 18, 2023
In addition, bisphosphonates, denosumab, and other bone-modifying agents showed a significantly higher risk of developing MRONJ owing to the changes in salivary microbiome profiles, cytokine profiles, interleukins, hypotaurine, and binding proteins...However, due to the availability of limited evidence, the findings of the review should be interpreted with caution. https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022327645.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review. (Pubmed Central) - Sep 18, 2023
The findings suggest that denosumab reduces the risk of fractures and improves bone mineral density in all stages of CKD. The results of this review support the use of denosumab as a promising option for managing bone disease in CKD and HD patients.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: The Effect of Denosumab in Elderly Patients Regarding Bone Density and Fracture Risk. (Pubmed Central) - Sep 18, 2023
The results of this review support the use of denosumab as a promising option for managing bone disease in CKD and HD patients. Denosumab use resulted in long-term BMD increase and reduced fracture risk in individuals aged 80 and above.